Scientists pinpoint metformin’s brain pathway, offering new clues for targeted type 2 diabetes treatment

After more than 60 years as a first-line drug for type 2 diabetes, metformin is yielding a clearer explanation for how it lowers blood sugar. Researchers report that part of its glucose-lowering effect depends on a specific brain circuit, not only the liver or the gut.

The study, led by Baylor College of Medicine and international collaborators, was published in Science Advances. It focuses on the ventromedial hypothalamus, a brain region known to help regulate whole-body metabolism.

A protein switch in the hypothalamus

The team centered on Rap1, a small signaling protein active in the ventromedial hypothalamus. They found that clinically relevant metformin dosing relied on suppressing Rap1 activity in this brain area to reduce blood glucose.

To test the mechanism, the researchers used mice engineered to lack Rap1 in the ventromedial hypothalamus and then fed them a high-fat diet to model diabetes. In those mice, low-dose metformin did not improve blood sugar, while insulin and GLP-1–based drugs still worked.

Why tiny brain doses mattered

In another experiment, researchers delivered extremely small amounts of metformin directly into the brains of diabetic mice. Even at doses thousands of times lower than typical oral exposure, blood glucose fell markedly, supporting a central nervous system effect.

The study also identified SF1 neurons in the ventromedial hypothalamus as key responders, becoming activated when metformin reached the brain. Electrophysiology data suggested metformin increased activity in most of these neurons, but only when Rap1 signaling was intact.

What it could mean next

The findings add to a growing view that metformin’s benefits may come from multiple organs working together, with the brain reacting at comparatively low drug levels. The authors argue that mapping this pathway could help guide future diabetes therapies that more precisely target glucose control.

The researchers also pointed to broader interest in metformin’s neurological effects, including ongoing questions about brain aging. They plan to examine whether the same Rap1-linked signaling helps explain other observed effects of the drug beyond diabetes.